TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05453838

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral intake of one serving of the original and new product
Description: 1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral intake of one serving of the original and new product
Description: 1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
Study: NCT04818671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC
Study: NCT06506747

Intervention type: DEVICE
Intervention: Navigated Photogrammetry
Description: Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
Study: NCT06013371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124
Description: topical PDE4 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Description: matching placebo
Study: NCT06475729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate-Free Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate-Free Mirikizumab
Description: Administered SC
Study: NCT05165628

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CYP-006TK
Description: CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
Study: NCT05433974

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection : 2 X 6 mL
Study: NCT06506747

Intervention type: DEVICE
Intervention: Standard Photogrammetry
Description: The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
Study: NCT05840991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elastic bandage
Description: 3M™ Coban™ elastic bandage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: elastic bandage
Description: 3M™ Coban™ elastic bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression stocking
Description: Class 2 compression full-length stocking (23-32mm Hg)
Study: NCT04990102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
Study: NCT05324956

Intervention type: OTHER
Intervention: No intervention
Description: Individuals will not receive any interventions
Study: NCT06633250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Formula
Description: Hydrolyzed rice protein formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Commercially available extensively hydrolyzed cow's milk formula
Study: NCT06633536

Intervention type: DRUG
Intervention: Ravulizumab
Description: open-label arm with ravulizumab administrated within the scope of routine clinical practice
Study: NCT05250648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
Description: In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
Study: NCT04861636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthTRAC
Description: Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBWC
Description: Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
Study: NCT03647462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
Study: NCT05153564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.34 mg/mL
Description: Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3.0 mg/mL
Description: Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389 10 mg/mL
Description: NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389 30 mg/mL
Description: NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Study: NCT05250648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete cytoreductive surgery without HIPEC
Description: in the arm without HIPEC, only complete cytoreductive surgery will be performed
Study: NCT05819203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healsea Babykids
Description: 7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
Study: NCT05437367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization exercises
Description: Therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization exercises
Description: Therapeutic exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Postural correction exercises
Description: Therapeutic exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Postural correction exercises
Description: Therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Therapeutic exercises
Study: NCT05211414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Based Daily Excercise
Description: Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
Study: NCT06341868

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: KneeStim
Description: Participant will be randomized to either be in control or experimental group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeStim
Description: Participant will be randomized to either be in control or experimental group
Study: NCT04654117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultee-centered administrative consultation
Description: The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
Study: NCT06218485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making
Description: The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve-guided PCI strategy
Description: The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05
Study: NCT06394388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cuidando juntos
Description: Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD.
Study: NCT06647628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1708
Description: MK-1708 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1708
Description: MK-1708 oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension
Study: NCT06192108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT06110780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling.
Study: NCT04874298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint
Description: Peppermint
Study: NCT04933877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial plane block
Description: Serratus anterior plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial plane block
Description: Serratus anterior plane block
Study: NCT05346861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab plus chemotherapy
Description: Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
Study: NCT05651997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MACT
Description: * A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
Study: NCT05119452

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
Description: The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
Description: The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
Study: NCT06192108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Administered orally
Study: NCT06515002

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BI 3720931
Description: BI 3720931

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BI 3720931
Description: BI 3720931

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BI 3720931
Description: BI 3720931

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BI 3720931
Description: BI 3720931

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BI 3720931
Description: BI 3720931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo
Study: NCT05346861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with pyrotinib plus chemotherapy
Description: Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
Study: NCT03873428

Intervention type: OTHER
Group type: OTHER
Intervention: FES PET
Description: FES injection
Study: NCT04894227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell）
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell）
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell）
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT04729595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempol
Description: Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
Study: NCT05604066

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) Elastography
Description: Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
Study: NCT06515002

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhaler
Description: Inhaler for application of BI 3720931 and placebo
Study: NCT05318976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be delivered by subcutaneous injection once a week
Study: NCT05026866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered intravenously
Study: NCT05122936

Intervention type: COMBINATION_PRODUCT
Intervention: XRXPY-based Obesity Wellness Intervention(SOWI)
Description: It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
Study: NCT05604066

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) Elastography
Description: Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI structural imaging
Description: MRI structural imaging will be done at the same time as MR elastography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI structural imaging
Description: MRI structural imaging will be done at the same time as MR elastography.
Study: NCT04787263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR_Lenti T cell
Description: Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
Study: NCT05026866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously
Study: NCT05456581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Scotoma awareness' Training
Description: In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Training
Description: The task will be performed in the control group without the visible scotoma.
Study: NCT05354765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment